Evidence map›Paper›PMID 23150718›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2012

Regulation of allograft survival by inhibitory FcγRIIb signaling.

Chris J Callaghan, Thet Su Win, Reza Motallebzadeh, Thomas M Conlon, Manu Chhabra, Inês Harper, Siva Sivaganesh, Eleanor M Bolton, J Andrew Bradley, Rebecca J Brownlie and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Best practices of heart transplantation in mice.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Review
  2. The Role of Fc Gamma Receptors in Antibody-Mediated Rejection of Kidney Transplants.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Review
  3. Memory T cell-mediated rejection is mitigated by FcγRIIB expression on CD8American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  4. Review
  5. Prolongation of allograft survival by passenger donor regulatory T cells.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Fcγ Receptors in Solid Organ Transplantation.Current transplantation reports · 2016
    Review
  12. CD8 T-cell recognition of acquired alloantigen promotes acute allograft rejection.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  13. Review
  14. Article
  15. Article
  16. A modified method for heterotopic mouse heart transplantion.Journal of visualized experiments : JoVE · 2014
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Chris J CallaghanDepartment of Surgery, University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
Thet Su Win
Reza Motallebzadeh
Thomas M Conlon
Manu Chhabra
Inês Harper
Siva Sivaganesh
Eleanor M Bolton
J Andrew Bradley
Rebecca J Brownlie
Kenneth G C Smith
Gavin J Pettigrew
Bridge University · SSUniversity of Cambridge · GBAddenbrooke's Hospital · GB

Funding

British Heart Foundation FS/10/018/28193British Heart Foundation PG/08/069/25462Wellcome TrustWellcome Trust 083650/Z/07/Z
6 · The paper itself

Abstract

Fcγ receptors (FcγR) provide important immunoregulation. Targeting inhibitory FcγRIIb may therefore prolong allograft survival, but its role in transplantation has not been addressed. FcγRIIb signaling was examined in murine models of acute or chronic cardiac allograft rejection by transplanting recipients that either lacked FcγRIIb expression (FcγRIIb(-/-)) or overexpressed FcγRIIb on B cells (B cell transgenic [BTG]). Acute heart allograft rejection occurred at the same tempo in FcγRIIb(-/-) C57BL/6 (B6) recipients as wild type recipients, with similar IgG alloantibody responses. In contrast, chronic rejection of MHC class II-mismatched bm12 cardiac allografts was accelerated in FcγRIIb(-/-) mice, with development of more severe transplant arteriopathy and markedly augmented effector autoantibody production. Autoantibody production was inhibited and rejection was delayed in BTG recipients. Similarly, whereas MHC class I-mismatched B6.K(d) hearts survived indefinitely and remained disease free in B6 mice, much stronger alloantibody responses and progressive graft arteriopathy developed in FcγRIIb(-/-) recipients. Notably, FcγRIIb-mediated inhibition of B6.K(d) heart graft rejection was abrogated by increasing T cell help through transfer of additional H2.K(d)-specific CD4 T cells. Thus, inhibitory FcγRIIb signaling regulates chronic but not acute rejection, most likely because the supra-optimal helper CD4 T cell response in acute rejection overcomes FcγRIIb-mediated inhibition of the effector B cell population. Immunomodulation of FcγRIIb in clinical transplantation may hold potential for inhibiting progression of transplant arteriopathy and prolonging transplant survival.

Indexed as

Acute DiseaseAnimalsChronic DiseaseGraft RejectionGraft SurvivalHeart TransplantationHep G2 CellsHumansImmunoglobulin GIsoantibodiesMiceMice, Inbred BALB CMice, Inbred C57BLMice, Inbred CBAMice, KnockoutMice, TransgenicFcgr2b protein, mouseImmunoglobulin GIsoantibodiesReceptors, IgG

Identifiers

PMID23150718
PMCPMC3605772
OpenAlexW2131342607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.